Publication:
Effect of WF10 (Immunokine) on Diabetic Foot Ulcer Therapy: A Double-blind, Randomized, Placebo-controlled Trial

0
0

Issued Date

2011

Resource Type

Article

File Type

application/pdf

ISSN

10672516

DOI

10.1053/j.jfas.2011.05.006

Other identifier(s)

2-s2.0-80054957456

Rights Holder(s)

มหาวิทยาลัยศรีนครินทรวิโรฒ

Bibliographic Citation

Journal of Foot and Ankle Surgery. Vol 50, No.6 (2011), p.635-640

Suggested Citation

Yingsakmongkol N., Maraprygsavan P., Sukosit P. Effect of WF10 (Immunokine) on Diabetic Foot Ulcer Therapy: A Double-blind, Randomized, Placebo-controlled Trial. Journal of Foot and Ankle Surgery. Vol 50, No.6 (2011), p.635-640. doi:10.1053/j.jfas.2011.05.006 Retrieved from: https://hdl.handle.net/20.500.14740/7223

Title

Effect of WF10 (Immunokine) on Diabetic Foot Ulcer Therapy: A Double-blind, Randomized, Placebo-controlled Trial

Author(s)

Yingsakmongkol N.
 Maraprygsavan P.
 Sukosit P.

Abstract

This randomized controlled trial was undertaken to evaluate the effect of WF10 (Immunokine) as an adjunct to the standard treatment of diabetic foot ulcer. A total of 40 participants were randomized into 2 groups of 20. One group underwent standard therapy combined with infusions of WF10, and 1 underwent standard therapy combined with placebo. The wound severity scores, which vary with the severity of infection and inflammation, necrotic and granulation tissues, and wound depth and area, were assessed weekly for 9 weeks. Before treatment, the wound severity scores were not significantly different statistically between the 2 groups (13.7 ± 2.8 and 12.9 ± 3.2). After 9 weeks, the WF10 group had a statistically significant decreased wound severity score compared with that of the placebo group (1.8 ± 1.9 versus 4.4 ± 5.3, respectively, p < .05). Subgroup analyses comparing the WF10 and placebo groups showed statistically significant decreases of infection and inflammation (0.0 ± 0.0 versus 0.8 ± 0.9, respectively, p < .01), necrotic tissue (0.0 ± 0.0 versus 0.8 ± 1.1, respectively, p < .01), and an increase of the amount of granulation tissue (0.1 ± 0.3 versus 0.8 ± 1.2, respectively, p < .05). The wound depth and wound area also decreased more in the WF10 group; however, these decreases were not statistically significant. No severe adverse events were observed throughout the observation period. We concluded that the addition of WF10 to standard wound care statistically significantly reduced the wound severity score, infection and inflammation, and necrotic tissue and enhanced the formation of granulation tissue. © 2011 American College of Foot and Ankle Surgeons.

Subject(s)

Immunokine
 Placebo
 Tetrachlorodecaoxide
 Unclassified drug
 Adjuvant therapy
 Adult
 Article
 Clinical article
 Controlled study
 Diabetic foot
 Disease severity
 Double blind procedure
 Drug efficacy
 Drug safety
 Female
 Granulation tissue
 Human
 Male
 Multiple cycle treatment
 Randomized controlled trial
 Side effect
 Skin inflammation
 Skin necrosis
 Thrombophlebitis
 Treatment outcome
 Wound assessment
 Wound infection
 Aged
 Chlorine
 Combined Modality Therapy
 Debridement
 Diabetic Foot
 Dose-Response Relationship, Drug
 Double-Blind Method
 Drug Administration Schedule
 Female
 Follow-Up Studies
 Granulation Tissue
 Humans
 Infusions, Intravenous
 Male
 Middle Aged
 Oxides
 Reference Values
 Severity of Illness Index
 Skin Care
 Treatment Outcome
 Wound Healing

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/7223

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By